ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options

Rhea-AI Filing Summary

ArriVent BioPharma director Kristine Peterson received a new stock option grant. She was awarded a non-qualified option covering 13,562 shares of common stock at an exercise price of $31.74 per share. The option vests on the first anniversary of the grant date, contingent on her continued service, and expires on June 17, 2036. Following this grant, she holds 13,562 derivative securities directly from this award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Peterson Kristine

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	13,562	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 13,562 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 13,562 shares Exercise price: $31.74 per share Expiration date: June 17, 2036 +1 more

4 metrics

Option grant size 13,562 shares Non-qualified stock option awarded to director

Exercise price $31.74 per share Strike price for the non-qualified stock option

Expiration date June 17, 2036 Option term end date

Holdings after grant 13,562 derivative securities Total options held following this transaction

Key Terms

Non-Qualified Stock Option, exercise price, vest, expiration date

4 terms

Non-Qualified Stock Option financial

"She was awarded a non-qualified option covering 13,562 shares of common stock"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

exercise price financial

"at an exercise price of $31.74 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The option vests on the first anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

expiration date financial

"and expires on June 17, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peterson Kristine

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD SUITE 100

(Street)

NEWTOWN SQUARE PENNSYLVANIA 19073

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$31.74	06/18/2026		A		13,562		06/18/2027(1)	06/17/2036	Common Stock	13,562	$0.00	13,562	D

Explanation of Responses:

1. The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.

	By: /s/ James Kastenmayer, Attorney-in-Fact for: Kristine Peterson	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ArriVent BioPharma (AVBP) report in this Form 4 for Kristine Peterson?

ArriVent BioPharma reported that director Kristine Peterson received a grant of non-qualified stock options for 13,562 shares. These options give her the right to buy common stock at a fixed exercise price in the future, subject to vesting conditions.

How many ArriVent BioPharma (AVBP) shares are covered by the new option grant?

The option grant covers 13,562 shares of ArriVent BioPharma common stock. This represents the number of shares she may purchase if the option vests and is exercised, giving her potential future equity exposure to the company.

What is the exercise price of Kristine Peterson’s ArriVent BioPharma (AVBP) stock options?

The exercise price of the non-qualified stock options is $31.74 per share. This is the fixed price at which she can buy ArriVent BioPharma common stock once the options vest and she chooses to exercise them.

When do Kristine Peterson’s ArriVent BioPharma (AVBP) options vest and expire?

The options vest on the first anniversary of the grant date, subject to her continued service. They expire on June 17, 2036, providing a long-term window during which vested options may be exercised if she chooses.

Is Kristine Peterson buying or selling ArriVent BioPharma (AVBP) shares in this Form 4?

This Form 4 shows an acquisition of stock options as compensation, not a market purchase or sale of shares. The transaction is a grant of non-qualified options, giving future purchase rights rather than immediate trading in the company’s stock.

How many ArriVent BioPharma (AVBP) derivative securities does Kristine Peterson hold after this grant?

After the reported transaction, Kristine Peterson holds 13,562 derivative securities from this option grant. This figure reflects the full size of the newly awarded non-qualified stock option position as disclosed in the filing.